Lillebaelt Hospital

Vejle 9 trials 4 recruiting

9 Registered trials

4 Currently recruiting

Organisation

Lillebaelt Hospital

Location

Vejle, Denmark

Identifier

ORG-100028132

Address

Sygehusvej 24, 6000, Denmark

Departments

1704: Reumatologisk Afsnit - Intern Medicin
Department of Hematology
Department of Oncology
Department of Plastic Surgery
Dept. of Internal Medicine
Lungemed. Amb
Medicine
Oncology Department
Otorhinolaryngology

Clinical trials at this site (9)

Search interface

DAN-WAR-D - Danish Warfarin-Dialysis Study: Safety and efficacy of warfarin in patients with atrial fibrillation on dialysis -A nationwide p… Recruiting

2022-502500-75-00 Atrial fibrillation 6 2024-01-30
Does peri-operative treatment with Tranexamic Acid reduce the early relapse rate for patients with melanoma; a randomised controlled trial Recruiting

2022-502633-26-00 Melanoma Surgery 5 2023-08-25
Immunotherapy in patients with early dMMR rectal cancer. A Danish DCCG phase II trial Recruiting

2022-500646-14-00 cancer 4 2023-01-31
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
Biologic treatment of rhinosinusitis with nasal polyposis in real-world Danish patients - a direct comparison of dupilumab and mepolizumab Ended

2022-502250-14-00 Chronic rhinosinusitis with nasal polyposis 6 2023-04-13
Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Mult… Ended

2022-500861-29-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2023-01-12
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a… Ended

2022-501895-25-00 Polymyalgia Rheumatica 5 2023-09-13
Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended

2022-501063-41-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-04-20